Idorsia Earnings Call Signals Turnaround, Risks Linger

Idorsia Ltd ((CH:IDIA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Idorsia’s latest earnings call painted a cautiously upbeat picture of a company in the midst of a tangible turnaround. Management highlighted surging product sales, sharp cost cuts, and stronger liquidity as proof that the business model is starting to work, while openly acknowledging persistent losses, U.S. regulatory overhangs, and reliance on partnerships to fully unlock its pipeline.

QUVIVIQ Sales Surge and Beat Guidance

QUVIVIQ was the star of the quarter, with product sales jumping from roughly CHF 60–61 million in 2024 to CHF 134 million in 2025, an increase of about 123 percent. This helped drive total net revenue to CHF 214 million, comfortably ahead of the upgraded 2025 guidance of CHF 130 million for QUVIVIQ and setting the base for a planned rise to about CHF 200 million in 2026.

EUCAN Region Leads Commercial Momentum

Regional performance was particularly strong in Europe and Canada, where QUVIVIQ sales soared from CHF 32 million to CHF 108 million in 2025, a gain of about 238 percent. Management emphasized that EUCAN has become the main engine of QUVIVIQ growth, offsetting flat trends in the U.S. and validating the product’s international potential.

Operating Losses Narrow Significantly

On profitability, Idorsia showed marked progress, cutting its non‑GAAP operating loss from CHF minus 308 million in 2024 to CHF minus 100 million in 2025, a roughly 67.5 percent improvement. Under U.S. GAAP, the EBIT loss narrowed to CHF minus 33 million, signaling that the company is moving closer to break‑even even though it remains clearly in the red.

Liquidity Bolstered With New Facilities

The balance sheet ended 2025 on firmer ground, with year‑end liquidity of CHF 89 million in cash and access to an additional CHF 80 million, for total available liquidity of CHF 169 million. Idorsia also highlighted a CHF 150 million funding facility, from which CHF 70 million was already drawn, and about CHF 68 million of net equity raised to support operations.

Cost Cuts and Balance Sheet Gains

Cost rationalization efforts delivered more than CHF 80 million in savings versus 2024, reflecting a leaner commercial and R&D footprint. In parallel, renegotiations cut Idorsia’s cost‑sharing commitments by USD 100 million, generating a one‑time CHF 90 million gain in the first quarter of 2025 and easing future cash needs.

TRYVIO / JERAYGO: Approvals and Clinical Edge

For hypertension therapy aprocitentan, marketed as TRYVIO or JERAYGO, Idorsia reported approvals across the U.S., EU, and other markets and noted that a prior safety program requirement was lifted in early 2025. The pivotal PRECISION trial showed a double‑digit blood pressure reduction of 15.4 millimeters of mercury within four weeks, with a favorable safety profile and inclusion in updated clinical guidelines later in 2025.

Encouraging Early Uptake for TRYVIO

Commercial preparations for TRYVIO are underway, with the drug already being used at more than 25 top hypertension centers during prelaunch activities. Management cited rising new patient starts, improving refill rates, and smooth prior authorization in key segments as early signs that the product could gain traction once fully launched.

Pipeline Advances and Lucerastat Roadmap

Beyond marketed drugs, Idorsia pushed three chemokine receptor antagonists into clinical testing, targeting psoriasis, multiple sclerosis, and vitiligo. For Fabry disease candidate lucerastat, the company agreed on a development path with regulators, including a pivotal biopsy‑based study and a switch study, with an eye on a possible regulatory filing around 2029.

Global Expansion and Local Wins for QUVIVIQ

QUVIVIQ’s global footprint expanded with public reimbursement secured in major European markets such as France, Germany, and the U.K., as well as private coverage in Switzerland and Canada. Additional reimbursement progress and strong fourth‑quarter demand, including double‑digit percentage demand gains in Germany, Canada, and the U.K., plus substantial private‑market uptake in China via partner Simcere, underpinned the growth story.

Pediatric Daridorexant Study Nears Readout

Idorsia completed recruitment for a pediatric daridorexant trial in patients aged 10 to 18, with data expected in early second quarter 2026. Management sees the potential for this to become the first approved pediatric insomnia treatment, which could broaden the franchise and support safety perceptions in the U.S. market.

Profitability Still Out of Reach

Despite the operational improvements, Idorsia remains loss‑making, posting a non‑GAAP operating loss of CHF minus 100 million and a U.S. GAAP net loss of CHF minus 112 million in 2025. Financial expenses totaled CHF 72 million, driven largely by a CHF 61 million noncash charge related to restructuring of a convertible bond, keeping the bottom line under pressure.

U.S. Headwinds for QUVIVIQ

In the U.S., QUVIVIQ sales were flat in 2025 despite global momentum and sizable cuts in sales and marketing expenses. The drug’s status under controlled‑substance regulations has created distribution friction, with pharmacies not consistently stocking it, so management is pinning hopes on regulatory changes and a label‑enhancing study to unlock meaningful access.

Descheduling Process Remains Uncertain

Progress toward easing U.S. prescribing restrictions depends on a regulatory process whose timing and outcome remain unclear. While Idorsia is running a label study and testing new distribution pilots to mitigate access barriers, it acknowledged that regulatory uncertainty is a significant risk for QUVIVIQ’s U.S. growth trajectory.

TRYVIO Commercialization Hinges on a Partner

The company is still engaged in partnership talks for TRYVIO and JERAYGO after a prior exclusive arrangement failed to close, although Idorsia did receive a USD 35 million fee. Without a finalized partner, scaling commercialization in hypertension will be harder and may constrain the pace and reach of the launch.

Cash Runway Adequate but Not Ample

Management described the current liquidity of CHF 169 million as sufficient to fund the business to upcoming inflection points such as regulatory decisions and key partnerships. However, they also emphasized that funding needs beyond those milestones, especially for multiple R&D programs, will likely depend on successful deals and external cash flows.

Long Timelines and Study Design Risks

The development path for lucerastat underscores the long lead times before potential revenue, with a possible filing not expected until around 2029. In addition, a planned renal function study is not designed to deliver statistically significant results on kidney outcomes, which could introduce extra regulatory or commercial risk.

Accounting Noise from One‑Off Items

Reported GAAP numbers were affected by one‑off and noncash financial charges, particularly the CHF 61 million expense from convertible bond restructuring. These items added volatility to financial statements and complicate year‑on‑year comparisons, even as underlying operations improved.

Reliance on Partnerships and Market Conditions

Idorsia’s growth strategy is tightly linked to securing and executing external partnerships for regions such as Latin America and Central and Eastern Europe as well as for key products like TRYVIO. Management also flagged the broader pricing and payer environment as a potential brake on commercialization, adding another external variable to the investment case.

Guidance Points to First Positive Commercial Contribution

Looking ahead, Idorsia guided QUVIVIQ sales of around CHF 200 million for 2026, up from CHF 134 million in 2025 and assuming flat operating expenses including cost of goods. The company expects this combination to deliver its first positive commercial contribution and push overall losses closer to profitability and cash‑flow break‑even, while keeping formal guidance to a one‑year horizon given multiple near‑term catalysts.

Idorsia’s earnings call sketched a story of genuine commercial momentum and disciplined cost control, counterbalanced by ongoing losses and significant execution risk. For investors, the next phase will hinge on U.S. regulatory outcomes, the signing of a strong TRYVIO partner, and steady progress in the pipeline, all of which could determine whether the current turnaround becomes a sustainable, profitable growth story.